Literature DB >> 10487566

Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases.

D Kondziolka1, A Patel, L D Lunsford, A Kassam, J C Flickinger.   

Abstract

PURPOSE: Multiple brain metastases are a common health problem, frequently diagnosed in patients with cancer. The prognosis, even after treatment with whole brain radiation therapy (WBRT), is poor with average expected survivals less than 6 months. Retrospective series of stereotactic radiosurgery have shown local control and survival benefits in case series of patients with solitary brain metastases. We hypothesized that radiosurgery plus WBRT would provide improved local brain tumor control over WBRT alone in patients with two to four brain metastases.
METHODS: Patients with two to four brain metastases (all < or =25 mm diameter and known primary tumor type) were randomized to initial brain tumor management with WBRT alone (30 Gy in 12 fractions) or WBRT plus radiosurgery. Extent of extracranial cancer, tumor diameters on MRI scan, and functional status were recorded before and after initial care.
RESULTS: The study was stopped at an interim evaluation at 60% accrual. Twenty-seven patients were randomized (14 to WBRT alone and 13 to WBRT plus radiosurgery). The groups were well matched to age, sex, tumor type, number of tumors, and extent of extracranial disease. The rate of local failure at 1 year was 100% after WBRT alone but only 8% in patients who had boost radiosurgery. The median time to local failure was 6 months after WBRT alone (95% confidence interval [CI], 3.5-8.5) in comparison to 36 months (95% CI, 15.6-57) after WBRT plus radiosurgery (p = 0.0005). The median time to any brain failure was improved in the radiosurgery group (p = 0.002). Tumor control did not depend on histology (p = 0.85), number of initial brain metastases (p = 0.25), or extent of extracranial disease (p = 0.26). Patients who received WBRT alone lived a median of 7.5 months, while those who received WBRT plus radiosurgery lived 11 months (p = 0.22). Survival did not depend on histology or number of tumors, but was related to extent of extracranial disease (p = 0.02). There was no neurologic or systemic morbidity related to stereotactic radiosurgery.
CONCLUSIONS: Combined WBRT and radiosurgery for patients with two to four brain metastases significantly improves control of brain disease. WBRT alone does not provide lasting and effective care for most patients.

Entities:  

Mesh:

Year:  1999        PMID: 10487566     DOI: 10.1016/s0360-3016(99)00198-4

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  206 in total

Review 1.  Radiotherapy for brain tumors.

Authors:  M P Mehta; W A Tomé; G H Olivera
Journal:  Curr Oncol Rep       Date:  2000-09       Impact factor: 5.075

2.  Central nervous system cancers, version 2.2014. Featured updates to the NCCN Guidelines.

Authors:  Louis Burt Nabors; Jana Portnow; Mario Ammirati; Henry Brem; Paul Brown; Nicholas Butowski; Marc C Chamberlain; Lisa M DeAngelis; Robert A Fenstermaker; Allan Friedman; Mark R Gilbert; Jona Hattangadi-Gluth; Deneen Hesser; Matthias Holdhoff; Larry Junck; Ronald Lawson; Jay S Loeffler; Paul L Moots; Maciej M Mrugala; Herbert B Newton; Jeffrey J Raizer; Lawrence Recht; Nicole Shonka; Dennis C Shrieve; Allen K Sills; Lode J Swinnen; David Tran; Nam Tran; Frank D Vrionis; Patrick Yung Wen; Nicole R McMillian; Maria Ho
Journal:  J Natl Compr Canc Netw       Date:  2014-11       Impact factor: 11.908

Review 3.  Neurosurgical management of metastases in the central nervous system.

Authors:  Elizabeth B Claus
Journal:  Nat Rev Clin Oncol       Date:  2011-12-06       Impact factor: 66.675

4.  [Radiotherapy of singular brain metastases].

Authors:  Stefanie Windischbauer; Felix Sedlmayer
Journal:  Wien Med Wochenschr       Date:  2010-02

Review 5.  Whole-brain radiation therapy in breast cancer patients with brain metastases.

Authors:  Cyrus Chargari; François Campana; Jean-Yves Pierga; Lionel Védrine; Damien Ricard; Sylvestre Le Moulec; Alain Fourquet; Youlia M Kirova
Journal:  Nat Rev Clin Oncol       Date:  2010-07-13       Impact factor: 66.675

Review 6.  The impact of cerebral metastases growth pattern on neurosurgical treatment.

Authors:  Marcel A Kamp; Philipp J Slotty; Jan F Cornelius; Hans-Jakob Steiger; Marion Rapp; Michael Sabel
Journal:  Neurosurg Rev       Date:  2016-07-09       Impact factor: 3.042

Review 7.  The role of whole brain radiation therapy for the management of brain metastases in the era of stereotactic radiosurgery.

Authors:  Eisuke Abe; Hidefumi Aoyama
Journal:  Curr Oncol Rep       Date:  2012-02       Impact factor: 5.075

Review 8.  Temozolomide for treatment of brain metastases: A review of 21 clinical trials.

Authors:  Wei Zhu; Li Zhou; Jia-Qi Qian; Tian-Zhu Qiu; Yong-Qian Shu; Ping Liu
Journal:  World J Clin Oncol       Date:  2014-02-10

9.  The treatment of patients with 1-3 brain metastases: is there a place for whole brain radiotherapy alone, yet? A retrospective analysis.

Authors:  Michela Buglione; Sara Pedretti; Stefano Gipponi; Luciano Buttolo; Paolo Panciani; Pietro Luigi Poliani; Roberto Liserre; Paolo Borghetti; Ludovica Pegurri; Loredana Costa; Luca Triggiani; Nadia Pasinetti; Paolo Ghirardelli; Sara Pandini; Alessandro Padovani; Stefano Maria Magrini
Journal:  Radiol Med       Date:  2015-04-28       Impact factor: 3.469

10.  The developing role for intensity-modulated radiation therapy (IMRT) in the non-surgical treatment of brain metastases.

Authors:  A A Edwards; E Keggin; P N Plowman
Journal:  Br J Radiol       Date:  2009-12-17       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.